Sugar-Coated Nanocarriers Deliver Herbal Compound to Shield Liver From Chemotherapy Damage

Methotrexate is one of the most widely prescribed drugs in modern medicine, deployed against cancers ranging from leukemia to osteosarcoma and against autoimmune conditions such as rheumatoid arthritis and psoriasis. Yet its clinical power comes with a notorious drawback: the drug can ravage the liver, and that hepatotoxicity often forces oncologists and rheumatologists to cap doses or abandon treatment altogether. A new study published in BMC Pharmacology and Toxicology offers a strikingly elegant potential solution, one that borrows a trick from the liver’s own biology. Researchers led by Liya Yang and Shihao Huang of Yueqing People’s Hospital, affiliated with Wenzhou Medical University, report that a galactose-decorated nanocarrier can ferry a protective plant compound directly into hepatocytes, dramatically blunting both acute and chronic methotrexate-induced liver injury in animal models.

The protective payload at the heart of the study is marein, a flavonoid glycoside derived from Coreopsis tinctoria, a flowering plant long used in traditional medicine. Previous work has suggested that marein carries genuine hepatoprotective potential, with antioxidant and anti-inflammatory activity. But like many promising natural products, marein suffers from two crippling pharmacological weaknesses: it dissolves poorly in water, making it difficult to formulate and deliver through the bloodstream, and it enters liver cells inefficiently, so little of an administered dose ever reaches its intended intracellular targets. These limitations have kept marein on the sidelines of translational research despite its biochemical promise.

The research team’s answer was to wrap marein inside micelles, self-assembling spheres built from DSPE-PEG, a biocompatible lipid-polymer conjugate already used in approved drug delivery systems. The hydrophobic core of each micelle swallows molecules of marein, solving the solubility problem in a single stroke, while the hydrophilic PEG shell stabilizes the particles in circulation and helps them evade the reticuloendothelial system, the body’s scavenging machinery that clears foreign particles from the blood. The decisive design feature, however, was the addition of galactose, a simple sugar, to the micelle surface. That modification transforms the carrier from a passive vehicle into a guided missile aimed squarely at liver cells.

The guidance mechanism exploits a receptor called the asialoglycoprotein receptor, or ASGPR, which sits on the surface of hepatocytes, the principal functional cells of the liver. ASGPR is a lectin, a sugar-binding protein whose natural job is to recognize and internalize glycoproteins bearing exposed galactose residues. Hepatocytes express it in abundance, which is precisely why it has become one of the most attractive targets in liver-directed drug delivery. By studding the micelle surface with galactose, the researchers ensured that hepatocytes would actively grab and engulf the carriers through receptor-mediated endocytosis, concentrating the payload inside the very cells that methotrexate damages most.

To confirm that this homing instinct actually works, the team turned to HepG2 cells, a human liver cancer cell line that retains hepatocyte characteristics. Using confocal laser scanning microscopy, they tracked fluorescently labeled micelles and observed markedly enhanced cellular uptake of the galactose-functionalized formulation compared with unmodified micelles. The result validated the core hypothesis of the study: decorating the particle surface with galactose genuinely boosts the efficiency with which liver cells internalize the encapsulated drug. Dynamic light scattering and physicochemical characterization confirmed that the micelles were properly formed, stable, and capable of carrying their cargo in a dispersible form.

Before moving into animal work, the researchers also deployed network pharmacology, a computational approach that maps the interactions among drugs, targets, and disease pathways. This analysis predicted that marein’s protective effects would flow through the PI3K-Akt and MAPK signaling cascades, central communication highways inside cells that govern survival, proliferation, and stress responses, along with broader inflammatory signaling networks. These predictions framed the mechanistic questions the team would then interrogate in vivo, turning the animal experiments into a test of a coherent mechanistic model rather than a mere efficacy survey.

The in vivo evaluation covered both faces of methotrexate hepatotoxicity: an acute injury model, capturing the rapid damage that follows a high dose, and a chronic model, mimicking the cumulative fibrotic scarring that emerges over repeated exposure. The outcomes were measured with the standard arsenal of hepatology. Serum levels of alanine aminotransferase and aspartate aminotransferase, the enzymes that spill into the bloodstream when hepatocytes die, served as the primary biomarkers of injury, while histopathological examination revealed the structural damage within liver tissue. Inflammation and apoptosis, the programmed death of liver cells, were quantified alongside fibrosis markers including alpha-smooth muscle actin and collagen I, proteins that signal activation of hepatic stellate cells and the laying down of scar tissue in the extracellular matrix.

The results told a consistent story across every endpoint. Compared with free marein and with unmodified marein-loaded micelles, the galactose-functionalized formulation significantly reduced serum ALT and AST elevations in both injury models. Liver tissue under the microscope showed correspondingly less damage, with diminished inflammatory cell infiltration and fewer apoptotic hepatocytes. In the chronic model, the targeted formulation suppressed the expression of alpha-smooth muscle actin and collagen I, indicating that it not only protected cells from immediate injury but also restrained the fibrotic remodeling process that constitutes the most dangerous long-term consequence of methotrexate hepatotoxicity. The alignment of these findings with the network pharmacology predictions suggests the PI3K-Akt and MAPK pathways and inflammatory signaling as the likely mechanistic underpinnings of the protection.

The comparative design of the study deserves particular attention, because it isolates the value of the targeting strategy itself. Free marein represents the unformulated compound, hobbled by poor solubility and weak uptake. Plain micelles solve the delivery problem in the bloodstream but lack a liver-homing signal. Only the galactose-decorated version achieved maximal protection, demonstrating that the benefit comes not merely from nanoformulation but from active receptor-directed delivery to hepatocytes. This distinction matters for the broader field, where the mere act of nano-packaging is sometimes credited with benefits that in fact depend on precise targeting ligands. The galactose-ASGPR pairing, long exploited in hepatology research, is here shown to elevate a modestly effective natural compound into a substantially more potent hepatoprotective agent.

The work, conducted under protocols approved by the Experimental Animal Welfare and Ethics Committee of Taizhou University and funded by municipal and provincial science programs in Zhejiang Province, remains at the preclinical stage, and the path from mouse models to human patients is long and uncertain. Dosing, safety, biodistribution, and interactions with methotrexate’s anticancer efficacy all require further study. Nevertheless, the study charts a clear translational concept: pair a hepatoprotective natural product with a sugar-guided nanocarrier to shield the liver from a mainstay chemotherapy and immunosuppressive drug. If the strategy survives further testing, patients undergoing methotrexate therapy could one day receive a protective co-treatment that accumulates precisely where the danger lies, turning the liver’s own sugar-recognizing machinery into an ally against drug-induced harm.

Subject of Research: Galactose-functionalized DSPE-PEG micelles for hepatocyte-targeted delivery of marein against methotrexate-induced liver injury

Article Title: Galactose‑functionalized DSPE–PEG‑based micelles for targeted delivery of marein: ameliorative effects and mechanisms against methotrexate‑induced acute and chronic liver injury

Article References: Yang, L., Haihua, C., Wang, Y., Qian, J., Liu, Y., Zhou, S., Kai, Q., Wang, X., & Huang, S. (2026). Galactose‑functionalized DSPE–PEG‑based micelles for targeted delivery of marein: ameliorative effects and mechanisms against methotrexate‑induced acute and chronic liver injury. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01231-y

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01231-y

Keywords: methotrexate, hepatotoxicity, marein, DSPE-PEG micelles, galactose, asialoglycoprotein receptor, nanomedicine, liver fibrosis, PI3K-Akt, MAPK, drug delivery, hepatoprotection